Catalyst Pharmaceuticals, Inc.
$26.07
▼
-0.52%
2026-04-21 06:12:00
catalystpharma.com
NCM: CPRX
Explore Catalyst Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.18 B
Current Price
$26.07
52W High / Low
$26.58 / $19.05
Stock P/E
14.85
Book Value
$7.79
Dividend Yield
—
ROCE
26.94%
ROE
25.49%
Face Value
—
EPS
$1.68
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
182
Beta
0.66
Debt / Equity
0.29
Current Ratio
6.08
Quick Ratio
5.82
Forward P/E
8.01
Price / Sales
5.2
Enterprise Value
$2.34 B
EV / EBITDA
7.91
EV / Revenue
3.97
Rating
None
Target Price
$34
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Pluri Inc. | $3.59 | — | $36.08 M | — | -348.95% | 669.52% | $7.13 / $2.82 | $-1.46 |
| 2. | Champions Oncology, Inc. | $6.08 | — | $84.36 M | — | 57.07% | -47.59% | $9.63 / $5.5 | $0.31 |
| 3. | Lexicon Pharmaceuticals, Inc. | $1.84 | — | $764.74 M | — | -29.8% | -39.72% | $1.95 / $0.49 | $0.3 |
| 4. | Korro Bio, Inc. | $14.28 | — | $207.54 M | — | -85.99% | -1.11% | $55.89 / $5.2 | $5.46 |
| 5. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
| 6. | Immunome, Inc. | $24.25 | — | $2.79 B | — | -35.12% | -52.09% | $27.65 / $6.96 | $5.61 |
| 7. | Aditxt, Inc. | $0.35 | — | $0.39 M | — | -318.91% | -6.99% | $2,594.48 / $0.39 | $-151.87 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 152.61 M | 148.39 M | 146.56 M | 141.42 M | 141.82 M | — |
| Operating Profit | 61.85 M | 66.27 M | 66.3 M | 63.37 M | 62.84 M | — |
| Net Profit | 52.7 M | 52.78 M | 52.11 M | 56.74 M | 55.94 M | — |
| EPS in Rs | 0.43 | 0.43 | 0.43 | 0.46 | 0.46 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 588.99 M | 491.73 M | 398.2 M | 214.2 M |
| Operating Profit | 257.78 M | 195.12 M | 86.81 M | 101.84 M |
| Net Profit | 214.33 M | 163.89 M | 71.41 M | 83.08 M |
| EPS in Rs | 1.75 | 1.34 | 0.58 | 0.68 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.1 B | 851.41 M | 470.11 M | 375.63 M |
| Total Liabilities | 149.71 M | 123.78 M | 82.23 M | 75.21 M |
| Equity | 954.27 M | 727.63 M | 387.88 M | 300.42 M |
| Current Assets | 894.03 M | 623.61 M | 219.33 M | 320.81 M |
| Current Liabilities | 147.15 M | 120.68 M | 76.06 M | 57.59 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 208.67 M | 239.81 M | 143.6 M | 116.05 M |
| Investing CF | -0.06 M | -0.56 M | -293.5 M | 9.21 M |
| Financing CF | -16.99 M | 140.66 M | -10.86 M | 1.69 M |
| Free CF | 208.61 M | 239.25 M | 61.86 M | 116.02 M |
| Capex | -0.06 M | -0.56 M | -81.74 M | -0.03 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 23.49% | 85.9% | — | — |
| Earnings Growth % | 129.5% | -14.05% | — | — |
| Profit Margin % | 33.33% | 17.93% | 38.79% | — |
| Operating Margin % | 39.68% | 21.8% | 47.54% | — |
| Gross Margin % | 86% | 86.95% | 83.94% | — |
| EBITDA Margin % | 47.36% | 30.06% | 48.12% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.